Dosage regimen of vidofludimus for use in the treatment of chronic inflammatory and / or autoimmune diseases
RS68050B1Active Publication Date: 2026-05-29IMMUNIC AG
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- RS68050P0
- Authority / Receiving Office
- RS · RS
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-22
- Filing Date
- 2018-11-22
- Publication Date
- 2026-05-29
- Estimated Expiration
- 2038-11-22
Need to check novelty before this filing date? Find Prior Art
No text content released.